Format

Send to

Choose Destination
Int J Tuberc Lung Dis. 2016 Jan;20(1):11-23. doi: 10.5588/ijtld.15.0472.

The global economic burden of asthma and chronic obstructive pulmonary disease.

Author information

1
Experimental Medicine Program, Department of Medicine, Faculty of Medicine, The University of British Columbia, Vancouver, Canada.
2
Department of Medicine, Division of Respiratory Medicine, The University of British Columbia, Vancouver, Canada; Institute for HEART + LUNG Health, Department of Medicine (Respiratory Division), The University of British Columbia, Vancouver, Canada; Centre for Clinical Epidemiology and Evaluation, The University of British Columbia, Vancouver, Canada.
3
Centre for Clinical Epidemiology and Evaluation, The University of British Columbia, Vancouver, Canada.

Abstract

Non-communicable diseases are now the number one cause of disabilities and loss of life expectancy. Among them, chronic respiratory conditions constitute a major class. The burden of chronic respiratory diseases is generally increasing across the globe, and asthma and chronic obstructive pulmonary disease (COPD) are among the main causes of mortality and morbidity. However, the direct and indirect costs of these conditions vary across jurisdictions. This article reports on recent estimates of the costs of asthma and COPD, with a focus on comparing disease burden across different regions. Overall, there is tremendous variation in per capita annual costs of asthma and COPD. However, the methodology of the cost-of-illness studies is also vastly different, making it difficult to associate differences in reported costs to differences in the true burden of asthma and COPD. Suggestions are provided towards improving the validity and comparability of future studies.

PMID:
26688525
DOI:
10.5588/ijtld.15.0472
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Ingenta plc
Loading ...
Support Center